Jan Roodt
Overview
Explore the profile of Jan Roodt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
277
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schochl H, van Griensven M, Heitmeier S, Laux V, Kipman U, Roodt J, et al.
Crit Care
. 2017 Mar;
21(1):51.
PMID: 28288667
Background: Inhibition of procoagulant pathways may improve outcome in sepsis. We examined whether a dual short-acting thrombin (factor II) and factor X (FX)a inhibitor (SATI) ameliorates sepsis-induced disseminated intravascular coagulation...
2.
Tersteeg C, Roodt J, Van Rensburg W, Dekimpe C, Vandeputte N, Pareyn I, et al.
Blood
. 2016 Dec;
129(8):1030-1038.
PMID: 28011677
Thrombotic thrombocytopenic purpura (TTP) is a microangiopathic disorder diagnosed by thrombocytopenia and hemolytic anemia, associated with a deficiency in von Willebrand factor (VWF)-cleaving protease ADAMTS13. Current treatment is based on...
3.
Callewaert F, Roodt J, Ulrichts H, Stohr T, Van Rensburg W, Lamprecht S, et al.
Blood
. 2012 Sep;
120(17):3603-10.
PMID: 22948047
ALX-0681 is a therapeutic Nanobody targeting the A1-domain of VWF. It inhibits the interaction between ultra-large VWF and platelet GpIb-IX-V, which plays a crucial role in the pathogenesis of thrombotic...
4.
Feys H, Roodt J, Vandeputte N, Pareyn I, Mottl H, Hou S, et al.
Blood
. 2012 Aug;
120(17):3611-4.
PMID: 22855603
The pathophysiology of thrombotic thrombocytopenic purpura (TTP) can be explained by the absence of active ADAMTS13, leading to ultra-large von Willebrand factor (UL-VWF) multimers spontaneously interacting with platelets. Preventing the...
5.
Ulrichts H, Silence K, Schoolmeester A, de Jaegere P, Rossenu S, Roodt J, et al.
Blood
. 2011 May;
118(3):757-65.
PMID: 21576702
Neutralizing the interaction of the platelet receptor gpIb with VWF is an attractive strategy to treat and prevent thrombotic complications. ALX-0081 is a bivalent Nanobody which specifically targets the gpIb-binding...
6.
Feys H, Roodt J, Vandeputte N, Pareyn I, Lamprecht S, Van Rensburg W, et al.
Blood
. 2010 Jun;
116(12):2005-10.
PMID: 20551375
Thrombotic thrombocytopenic purpura (TTP) is the prototypical microangiopathy characterized by disseminated microthromboses, hemolytic anemia, and ultimately organ dysfunction. A link with deficiency of the von Willebrand factor-cleaving protease (ADAMTS13) has...
7.
Fontayne A, Meiring M, Lamprecht S, Roodt J, Demarsin E, Barbeaux P, et al.
Thromb Haemost
. 2008 Oct;
100(4):670-7.
PMID: 18841291
The Fab-fragment of 6B4, a murine monoclonal antibody targeting the human platelet glycoprotein (GP) Ibalpha and blocking the binding of von Willebrand factor (VWF), is a powerful antithrombotic. In baboons,...
8.
De Meyer S, Staelens S, Badenhorst P, Pieters H, Lamprecht S, Roodt J, et al.
Thromb Haemost
. 2007 Dec;
98(6):1343-9.
PMID: 18064334
Revascularization techniques, such as angioplasty and stent implantation, frequently lead to restenosis due to the formation of neointima after platelet activation and the concomitant release of various smooth muscle cell...
9.
Fontayne A, Vanhoorelbeke K, Pareyn I, Van Rompaey I, Meiring M, Lamprecht S, et al.
Thromb Haemost
. 2006 Nov;
96(5):671-84.
PMID: 17080226
Fab-fragments of the monoclonal antibody 6B4, raised against human glycoprotein Ibalpha (GPIbalpha), have a powerful antithrombotic effect in baboons by blocking the GPIbalpha binding site for von Willebrand factor (VWF),...
10.
Goodrich R, Li J, Pieters H, Crookes R, Roodt J, Heyns A
Vox Sang
. 2006 Apr;
90(4):279-85.
PMID: 16635070
Background And Objectives: Changes in in vitro platelet quality parameters during platelet storage are associated with a decrease of in vivo platelet viability after platelet transfusion. Many attempts have been...